Gastroenterology
Feature
IBS: Understanding a Common Yet Misunderstood Condition
Today, several dietary, pharmacologic, and psychological/behavioral approaches are available to treat patients with IBS.
News
Live Rotavirus Vaccine Safe for Newborns of Biologic-Treated Moms With IBD
The study found normal extended immune function testing in infants despite third-trimester maternal biologic therapy and regardless of circulating...
News from the FDA/CDC
FDA Approves Ustekinumab Biosimilar Otulfi
This is the fourth ustekinumab biosimilar approved in the United States.
Commentary
Cancer Treatment 101: A Primer for Non-Oncologists
Doctor explains why he thinks time of diagnosis is the best time for molecular testing of a new malignant tumor.
Feature
When Childhood Cancer Survivors Face Sexual Challenges
The disruptions caused by cancer and its treatment can interfere with normal physiological and psychological development, leading to issues with...
From the Journals
US Experience With Infliximab Biosimilars Suggests Need for More Development Incentives
Use of infliximab biosimilars in the United States rose slowly until three were on the market; it continued to remain lower for Medicare than for...
Latest News
Case Series: Upadacitinib Effective for Granulomatous Cheilitis
Treatment resulted in a complete response in four patients within a median of 3.8 months and a partial response in one patient.
From the Journals
Ancient Viruses in Our DNA Hold Clues to Cancer Treatment
Targeting remnants of a virus in our DNA could lead to more effective cancer treatment with fewer side effects.
Letters from Maine
Opioids Post T&A
From the Journals
Dupilumab Effective in PPI-Refractory Pediatric EoE
The trial found that a higher-exposure dupilumab regimen improved key secondary end points.
News from the FDA/CDC
Pyzchiva Receives FDA Approval as Third Ustekinumab Biosimilar
The biosimilar is approved for all indications of the reference medication, Stelara, and will launch in February 2025.